SPARC is involved in the transition from DCIS to invasive ductal carcinoma via a TGFBR-dependent mechanism in breast cancer
Ductal carcinoma in situ (DCIS) presents a variable risk of progression to invasive ductal carcinoma (IDC), yet reliable predictors of this transition are limited. Membrane type I matrix metalloproteinase (MT1-MMP) is a key regulator of this progression. We combined RNA sequencing of MT1-MMPhigh and MT1-MMPlow cell populations from intraductal tumor xenografts with human high-grade DCIS datasets to identify regulators of early breast cancer progression. Data from 1100 breast cancer patients in The Cancer Genome Atlas (TCGA) were analyzed (Pearson's correlation). Protein expressions were analyzed by IHC on three independent human cohorts (n = 231, Friedman test). siRNA-mediated knockdown of Secreted Protein Acidic and Cysteine Rich (SPARC) and pharmacological inhibition of TGF-β receptor type I (TGFBR), gelatin degradation and cell migration assays were employed to analyze the role of the TGFBRI–SPARC–MT1-MMP axis in breast cancer invasion (ANOVA). A new intraductal syngeneic mice model was used for testing TGFBRI inhibitors in the DCIS-to-IDC transition (ANOVA). SPARC was identified as an invasive switch candidate, upregulated in DCIS versus normal epithelium, further increased in IDC, and correlated with MT1-MMP expression. Functionally, SPARC depletion reduced MT1-MMP, matrix degradation, and TGF-β signaling. TGFBRI inhibition decreased SPARC and MT1-MMP levels, matrix degradation, cell migration, and DCIS-to-IDC transition in a triple-negative intraductal syngeneic mouse model. Notably, SPARC did not associate with metastasis, confirming its specific role in early progression. Our findings highlight the TGFBRI–SPARC–MT1-MMP axis as a promising therapeutic target for preventing early breast cancer invasion.
Authors
- Naira Rodríguez Padilla (ORCID: https://orcid.org/0000-0002-3655-190X)
- Paola De Luca (ORCID: https://orcid.org/0000-0001-9810-8818)
- Tamara López-López (ORCID: https://orcid.org/0009-0000-9345-907X)
- Noelia Paola Cardozo
- Ana María Eiján (ORCID: https://orcid.org/0000-0002-2723-0194)
- Lina Marino
- Marianela Sciacca (ORCID: https://orcid.org/0009-0003-3040-7389)
- Katrina Podsypanina (ORCID: https://orcid.org/0000-0003-4711-0859)
- Anne Vincent‐Salomon (ORCID: https://orcid.org/0000-0001-5754-5771)
- Ivan Bièche (ORCID: https://orcid.org/0000-0002-2430-5429)
- María del Pilar Carballo
- Erica A. Rojas Bilbao
- Philippe Chavrier (ORCID: https://orcid.org/0000-0002-7351-733X)
- Mathieu Boissan (ORCID: https://orcid.org/0000-0001-6494-5722)
- Ezequiel Lacunza (ORCID: https://orcid.org/0000-0002-6731-9820)
- Catalina Lodillinsky (ORCID: https://orcid.org/0000-0002-4360-9743)
- Laura Courtois
- Pablo José Sáez (ORCID: https://orcid.org/0000-0003-0521-9426)
- Martin Abba
Institutions
- Centre National de la Recherche Scientifique (FR)
- Consejo Nacional de Investigaciones Científicas y Técnicas (AR)
- Inserm (FR)
- Universidad de Buenos Aires (AR)
- Université Paris Sciences et Lettres (FR)
- Sorbonne Université (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- University Medical Center Hamburg-Eppendorf (DE)
- Pitié-Salpêtrière Hospital (FR)
- Centre de Recherche Saint-Antoine (FR)
- Instituto de Oncología de Rosario (AR)
- Experimental Medicine and Biology Institute (AR)
- Institut Curie (FR)
- Universidad Nacional de La Plata (AR)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1186/s13058-026-02424-3
- Primary Topic
- TGF-β signaling in diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft
- Agencia Nacional de Promoción Científica y Tecnológica
- Secretaría de Ciencia y Técnica, Universidad de Buenos Aires